This trial is evaluating whether CC-220 will improve 2 primary outcomes and 14 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Up to 28 days from start of the combination therapy.
This trial requires 415 total participants across 3 different treatment groups
This trial involves 3 different treatments. CC-220 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"The aetiology of multiple myeloma is currently not well understood. However, the results showed that the MYC proto-oncogene is significantly down-regulated and methylation-linked DNA hypomethylation is associated with multiple myeloma development." - Anonymous Online Contributor
"Many patients have multiple myeloma at the time of diagnosis. When multiple myeloma is diagnosed, several treatment options are available. Treatment must first be tailored to individual patient needs, however, through clinical trials and collaborative arrangements with one of six Clinical Research Nurse Collaborative Centers (CRNCC) established by the United States Federal Government. The CRNCC Program was formulated to promote the advancement of multidisciplinary, multi-institutional clinical treatment research for patients with multiple myeloma, with an emphasis on prevention of disease progression through prevention and early detection, as well as to treat advanced disease." - Anonymous Online Contributor
"Results from a recent paper of the prospective studies indicate that MM at diagnosis with a low bone marrow blast percentage is typically curable, even if the disease is refractory. Therefore, MM therapy does not have to be continued after disease remission because it is not curable." - Anonymous Online Contributor
"In the U.S. in 2001, 21,700 people got multiple myeloma, with an estimated incidence rate of 2.8 per million per year among those 65 years of age and older. However, the mortality rate in people with multiple myeloma was twice as high as in the general population: 9 people per year per million were estimated to have died in 2001. The lifetime risk of developing multiple myeloma is approximately 3% for all age groups in the U.S., and is significantly higher for people 65 years and older." - Anonymous Online Contributor
"Multiple myeloma is a cancer of the bone marrow which forms tumours in the bones of the spine, ribs, skull, and other bones. Symptoms may include heavy feeling around the shoulders, legs or bones, headache, and unexplained back pain. A number of other symptoms may also occur. It usually occurs in people over the age of sixty, but in about 5% of cases symptoms will manifest before the age of 40. In most cases the cause remains unknown and treatment consists of chemotherapy and rarely bone marrow transplants. Survival rates have improved over recent years, partly because of earlier diagnosis as well as better drug responses." - Anonymous Online Contributor
"People presenting with symptoms of a myeloproliferative disease usually have myeloma. These symptoms include progressive malaise, increased urinary frequency, night sweats, increased weight and bone pain. Other signs include low red blood cells, low platelets and enlarged lymph nodes. In more advanced cases, bone pain and renal dysfunction may develop." - Anonymous Online Contributor
"The effectiveness and side effects of cc-220 were similar or even a bit better than nirvanon for the treatment of relapsed and refractory multiple myeloma. Further long-term trials are warranted." - Anonymous Online Contributor
"People with moderate symptoms, who have not had symptomatic improvement with standard therapy, with adequate renal and liver function, and a reasonably good performance status should consider taking part in a trial. It may be that the benefit of a trial is no better than that of usual care. It should be considered when no evidence shows that current treatment is effective, when some patients consider that their current treatment may not be right for them, or when there is reasonable confidence that the new treatment will help. It is recommended to contact the principal investigator or medical writer before taking part in a clinical trial." - Anonymous Online Contributor
"The treatment of MM is frequently ineffective. Although multiple myeloma is uncommon in patients older than 60 years of age, it has the potential to severely impair the quality of life of those with it." - Anonymous Online Contributor
"Bortezomib/dexamethasone is an effective and well-tolerated antineoplastic drug. It can produce objective responses in high-risk myeloma. It may be a valid option in high-risk and/or elderly patients, even if not yet proven to improve survival rates." - Anonymous Online Contributor
"As multiple myeloma is a serious disease with many complications, the advancement of understanding the pathogenesis of this disease should be a focus for clinical investigators." - Anonymous Online Contributor
"No novel discoveries have been made in the past 5 years in multiple myeloma research, though this is likely the result of the fact these patients are rarely studied in large studies; nevertheless, small clinical trials do continue to be performed." - Anonymous Online Contributor